Latest Healthcare It News

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Oneview Healthcare reported a €2.2 million net cash outflow in Q3 2025, impacted by delayed customer payments, while expanding its U.S. footprint with a new client and advancing deployments.

Unith Ltd reports a 32% rise in Q1 FY26 cash receipts and unveils its breakthrough Streaming Avatars technology, alongside a successful $1.85 million capital raise.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Smart Parking Limited reports a record FY25 with revenues up 42% to $77.2 million, driven by organic growth and strategic acquisitions including Peak Parking in the US. The company targets 3,000 managed sites by 2028, leveraging proprietary AI technology across multiple international markets.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Austco Healthcare kicks off FY26 with a robust 51% revenue increase and improved profitability, driven by strong organic growth and strategic acquisitions.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.